Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 10 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 1’510.00 |
Über diesen Artikel
NACRES:
NA.24
UNSPSC Code:
41116107
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltengrade
pharmaceutical primary standard
API family
risperidone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
General description
Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
Application
Risperidone System Suitability Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| manufacturer/tradename USP | manufacturer/tradename EDQM | manufacturer/tradename USP | manufacturer/tradename EDQM |
| grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical primary standard |
| application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) |
| format neat | format neat | format neat | format neat |
| API family risperidone | API family risperidone | API family risperidone | API family risperidone |
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Lagerklasse
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG
The New England Journal of Medicine, 346(1), 16-22 (2002)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G
Journal of Clinical Psychopharmacology, 13(1), 25-40 (1993)
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Kapur S
Life Sciences, 57(10), PL103-PL107 (1995)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1604665-10MG | 04061833854785 |